01/07/2026 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors Download PDF Category: 20261 July 2026Post navigationPreviousPrevious post:AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AMLNextNext post:AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s developmentRelated PostsAB Science web conference of October 14, 202614 October 2026Web conference on October 14, 2026, from 6:00 p.m. to 7:30 p.m.12 October 2026Revenues for the first half of 2026 and update on AB Science’s activities9 October 2026AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
